Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (March 2020)
20 slides from Can-fite Biopharma's investor presentation, Mar 9, 2020
Slide 1: Can-Fite Presentation March 2020
(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation March 2020 (NYSE American: CANF) (TASE:CFBI)
Slide 2: Forward Looking Statement
(NYSE American: CANF) (TASE:CFBI) Forward Looking Statement 2 • This presentation contains forward - looking statements, about Can - Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strate
Slide 3: Company Profile
(NYSE American: CANF) (TASE:CFBI) 3 Company Profile • Advanced clinical stage drug development company with a compelling platform technology • Small molecule drug products in Phase II and Phase III clinical studies; covered by 14 Patent Families • Highly experienced management, clinical and regulato
Slide 4: From Concept to Technology
(NYSE American: CANF) (TASE:CFBI) From Concept to Technology 4 Company platform technology mimics natural body mechanism to combat cancer and inflammation
Slide 5: Platform Technology: Therapeutic Target and Drug Product
(NYSE American: CANF) (TASE:CFBI) Therapeutic Target • A 3 adenosine receptor (A 3 AR) • Highly expressed in inflammatory and cancer cells Drug product • Small molecules • Orally bioavailable drugs Therapeutic Effect • Anti - inflammatory and anti - cancer effects shown in Phase II studies; Excellen
Slide 6: Drug Development Pipeline
(NYSE American: CANF) (TASE:CFBI) Drug Development Pipeline 6 ~$50.5B ~$11.3B ~$3.8B ~$35B ~$3.2B Market *Sources: iHealthcare Analyst estimates global psoriasis drug market will be $11.3 B by 2025 and the global rheumatoid arthri tis drug market will be $50.5 B by 2025; DelveInsight estimates the H
Slide 7: Cannabinoid-Based Pharmaceuticals & Assays
(NYSE American: CANF) (TASE:CFBI) 7 7 • Collaboration Rationale - Cannabinoids induce their therapeutic effects via binding to Can Fite ’ s drugs ’ target, the A 3 adenosine receptor • Intellectual Property - Can - Fite filed a patent protecting the discovery of cannabinoid - based treatment of dise
Slide 8: Corporate Partnerships: Out-licensing deals
(NYSE American: CANF) (TASE:CFBI) Corporate Partnerships: Out - licensing deals 8 ~$18 million* upfront and milestone payments received to date for licensing and distribution deals *$8.5M was from a license with a Japanese company, SKK; the license was terminated due to SKK’s strategic change of foc
Slide 9: Piclidenoson: Rheumatoid Arthritis, Psoriasis & COVID-19
(NYSE American: CANF) (TASE:CFBI) 9 Piclidenoson Rheumatoid Arthritis, Psoriasis & Coronavirus COVID - 19 Piclidenoson – Anti - Inflammatory Drug Mechanism of Action
Slide 10: Rheumatoid Arthritis - Phase IIb Data
(NYSE American: CANF) (TASE:CFBI) Phase IIb study, Placebo controlled; 79 patients – Positively concluded Rheumatoid Arthritis - Phase IIb Data 10 *MTX, Biological Drugs *MTX, Biological Drugs Patients with No Prior Systemic Therapy* ACR20 ACR50 ACR 70 ACR Response Rates Placebo (n=8) Piclidenoson (
Slide 11: Rheumatoid Arthritis - Phase III Study Ongoing
(NYSE American: CANF) (TASE:CFBI) Rheumatoid Arthritis - Phase III Study Ongoing ACRobat – Can - Fite’s Phase III clinical study is designed to establish Piclidenoson as non - inferior to MTX in newly diagnosed patients with moderate - to - severe RA This Protocol is in Agreement with EMA • Randomiz
Slide 12: Psoriasis Phase II/III Data vs. Celgene's Otezla
(NYSE American: CANF) (TASE:CFBI) Psoriasis Phase II/III Data vs. Celgene ’ s Otezla * 12 • Phase II/III study did not achieve the primary endpoint of PASI 75 at 12 weeks • Otezla® sales were $1.6 billion in 2018, 26% increase over 2017 1 • Peak Otezla® sales estimated at $3.1 billion 2 • Phase II/I
Slide 13: Psoriasis Phase III Study - Ongoing
(NYSE American: CANF) (TASE:CFBI) Psoriasis Phase III Study - Ongoing Comfort – Phase III clinical study is designed to establish Piclidenoson superiority vs. placebo and non - inferiority vs. Otezla in patients with moderate - to - severe Plaque Psoriasis This Protocol is in Agreement with EMA • Ra
Slide 14: Coronavirus COVID-19 – Exploring Collaborations
(NYSE American: CANF) (TASE:CFBI) Coronavirus COVID - 19 – Exploring Collaborations Rheumatoid arthritis drugs are being used to treat coronavirus COVID - 19 • Can - Fite is now actively exploring collaborations with leading virology labs to develop Piclidenoson as treatment for coronavirus • Piclid
Slide 15: Namodenoson: Advanced Liver Cancer & NASH
(NYSE American: CANF) (TASE:CFBI) 15 Namodenoson Advanced Liver Cancer & NASH Namodenoson – Liver Disease Drug Mechanism of Action
Slide 16: Liver Cancer - Phase II Data
(NYSE American: CANF) (TASE:CFBI) • While the study ( 78 patients) did not achieve its primary endpoint, it did achieve superiority in survival in the largest subpopulation of CPB 7 , 56 patients - 6.8 month median overall survival vs. 4.3 months for placebo • CPB 7 group treated with Namodenoson ha
Slide 17: End of Phase II Meeting with FDA; Preparatory Work for Phase III
(NYSE American: CANF) (TASE:CFBI) • Successfully Concluded End of Phase II Meeting with FDA An agreement on a pivotal Phase III design has been reached with FDA: • Double - blind, Placebo - controlled • Child Pugh B7 (CPB7) patients - 2 nd or 3 rd line • Oral treatment two times per day • Primary en
Slide 18: NASH – Excellent Pre-clinical Data
(NYSE American: CANF) (TASE:CFBI) NASH – Excellent Pre - clinical Data 18 Namodenoson markedly improved liver function & pathology in NASH experimental models (STAM & CCL4) x Anti - inflammatory - Namodenoson reduces NAFLD Activity Score (NAS) in STAM model x Anti - Fibrotic effect - in vitro and in
Slide 19: NASH – Phase II Study
(NYSE American: CANF) (TASE:CFBI) NASH – Phase II Study 19 • Multicenter, randomized, double - blinded, placebo - controlled, dose - finding efficacy and safety study 60 patients with NAFLD with or without NASH • Efficacy end points : Lately amended to include following parameters: 1. Mean % change
Slide 20: Spotlight on Milestones
(NYSE American: CANF) (TASE:CFBI) Spotlight on Milestones 20 *Sources: iHealthcare Analyst estimates global psoriasis drug market will be $11.3 B by 2025 and the global rheumatoid arthri tis drug market will be $50.5 B by 2025; DelveInsight estimates the HCC drug market at $3.8 b in 2027; Grand View
Can-Fite BioPharma — Investor Presentation (March 2020) on 6ix